(Q50457607)

14 March 2018

title

Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. (English)

1 reference

14 March 2018

1 reference

1 reference

Cristina L Zavaleta

1

1 reference

14 March 2018

Beth A Goins

2

1 reference

14 March 2018

Ande Bao

3

1 reference

14 March 2018

Linda M McManus

4

1 reference

14 March 2018

C Alex McMahan

5

1 reference

14 March 2018

William T Phillips

6

1 reference

14 March 2018

publication date

1 August 2008

1 reference

14 March 2018

Journal of Drug Targeting

published in

1 reference

14 March 2018

volume

16

1 reference

14 March 2018

issue

7

1 reference

14 March 2018

page(s)

626-637

1 reference

14 March 2018

Novel therapeutic agents in ovarian cancer

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Direct 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pretargeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Patterns and progress in ovarian cancer over 14 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Intraperitoneal chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Future trends in radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Antibody-guided radiation therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Intraperitoneal drug delivery of antineoplastics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Intraperitoneal antineoplastic drug delivery: rationale and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Mediastinal node and diaphragmatic targeting after intracavitary injection of avidin/99mTc-blue-biotin-liposome system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Current status of cancer therapy with radiolabeled monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Use of avidin/biotin-liposome system for enhanced peritoneal drug delivery in an ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Radionuclides and carrier molecules for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

Colorimetric determination of phospholipids with ammonium ferrothiocyanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10611860802230372

10.1080/10611860802230372

21 January 2018

Identifiers

DOI

1 reference

14 March 2018

1 reference

14 March 2018